Literature DB >> 2567914

Animal toxicology of iron chelator L1.

J B Porter, K P Hoyes, R Abeysinghe, E R Huehns, R C Hider.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2567914     DOI： 10.1016/s0140-6736(89)90206-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

Review 2.  Present status and future prospects of oral iron chelation therapy in thalassaemia and other diseases.

Authors:  G J Kontoghiorghes
Journal:  Indian J Pediatr       Date:  1993 Jul-Aug       Impact factor: 1.967

3.  Frequency of sensory neural hearing loss in major Beta-thalassemias in southern iran.

Authors:  Abolhassan Faramarzi; Mehran Karimi; Seyed-Taghi Heydari; Mahmoud Shishegar; Masoud Kaviani
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

Review 4.  A risk-benefit assessment of iron-chelation therapy.

Authors:  J B Porter
Journal:  Drug Saf       Date:  1997-12       Impact factor: 5.228

Review 5.  Drug antioxidant effects. A basis for drug selection?

Authors:  B Halliwell
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 6.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.